semaglutide anorexia GLP-1s have been hailed as miracle drugs, their rise leading to critical breakthroughs in America's fight against obesity. Roughly 13 million Americans are now on them, according to research from JPMorgan published Dangers of Taking Ozempic for

JAMA, 259 , 527532.

Save 10-15% off RRP on Flow State Offer ends 17.08.26

A: Nein

Key findings include: GLP3 monotherapy achieved 22.8-24.2% mean weight reduction at 48 weeks in phase 2 obesity trials (8-12 mg doses) Cagrilintide monotherapy produced 10.8% weight loss over 26 weeks in phase 2 studies (2.4 mg dose) CagriSema combination (cagrilintide + semaglutide) achieved 20.4% weight loss at 68 weeks in phase 3 REDEFINE trials Combination approaches consistently outperformed single-agent therapies across multiple dose ranges Studies demonstrated that 100% of participants receiving GLP3 8 mg or higher achieved at least 5% weight loss, with 75-83% achieving 15% or greater weight reduction[9]

until 2032